Partow Kebriaei

发表

Cord-blood engraftment with ex vivo mesenchymal-cell coculture.

Mark Munsell, Muzaffar H Qazilbash, Ian McNiece, 2012, The New England journal of medicine.

Bayesian Continual Reassessment Method for Dose-Finding Trials Infusing T Cells with Limited Sample Size

Yuan Ji, Ping Liu, Donald Berry, 2012, Journal of biopharmaceutical statistics.

Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells

S. Olivares, Harjeet Singh, H. Huls, 2013, PloS one.

Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

Xuelin Huang, Guillermo Garcia-Manero, Gautam Borthakur, 2016, British journal of haematology.

Individual Motile CD4+ T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells

Peng Qiu, Badrinath Roysam, Amine Merouane, 2015, Cancer Immunology Research.

A new approach to gene therapy using Sleeping Beauty to genetically modify clinical‐grade T cells to target CD19

Harjeet Singh, H. Huls, L. Cooper, 2014, Immunological reviews.

Acute lymphoblastic leukaemia: diagnosis and classification.

John Anastasi, R. Larson, J. Anastasi, 2002, Best practice & research. Clinical haematology.

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.

Luigi Naldini, Pei-Qi Liu, Chiara Bonini, 2012, Blood.

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.

Katy Rezvani, David A Largaespada, Jianliang Dai, 2016, The Journal of clinical investigation.

Toward eliminating HLA class I expression to generate universal cells from allogeneic donors.

Rudolf Jaenisch, R. Jaenisch, Jeffrey C. Miller, 2013, Blood.